Northwest Biotherapeutics (NWBO) Net Cash Flow (2010 - 2026)

Northwest Biotherapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$3.4 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 254.32% year-over-year to -$3.4 million in Q1 2026; TTM through Mar 2026 was -$2.9 million, a 288.93% decrease from a year earlier, with the FY2025 full-year figure at $2.7 million, up 320.63% from the prior year.
• Net Cash Flow retreated to -$3.4 million in Q1 2026 per NWBO's latest filing, from -$2.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $5.5 million in Q2 2025 and bottomed at -$9.1 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$560000.0 (2024), against an average of -$1.2 million.
• Across the five-year window, Net Cash Flow jumped 2662.04% in 2023 and plunged 5700.0% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at $342000.0 in 2022, then slumped by 965.79% to -$3.0 million in 2023, then plunged by 45.8% to -$4.3 million in 2024, then surged by 51.8% to -$2.1 million in 2025, then tumbled by 64.78% to -$3.4 million in 2026.
• Per Business Quant, the three latest NWBO Net Cash Flow figures stand at -$3.4 million (Q1 2026), -$2.1 million (Q4 2025), and -$2.8 million (Q3 2025).